Long-term Efficacy of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis in Two Phase 3 Trials and an Open-label Extension Trial

被引：0

作者：

Cree, B. A. ^{[1
]}

Selmaj, K. ^{[2
]}

Steinman, L. ^{[3
]}

Comi, G. ^{[4
,5
]}

Bar-Or, A. ^{[6
]}

Arnold, D. L. ^{[7
]}

Hartung, H. ^{[8
]}

Montalban, X. ^{[9
]}

Havrdova, E. K. ^{[10
,11
]}

Sheffield, J. K. ^{[12
]}

Cheng, C. ^{[12
]}

Riolo, J. V. ^{[12
]}

Silva, D. ^{[12
]}

Kappos, L. ^{[13
]}

Cohen, J. A. ^{[14
]}

机构：

[1] Weill Inst Neurosci, San Francisco, CA USA

[2] Ctr Neurol, Lodz, Poland

[3] Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, Stanford, CA USA

[4] Univ Vita Salute San Raffaele, Milan, Italy

[5] Casa Cura Policlin, Milan, Italy

[6] Ctr Neuroinflammat & Expt Therapeut, Dept Neurol, Philadelphia, PA USA

[7] NeuroRx Res & Montreal Neurol Inst, Montreal, PQ, Canada

[8] Heinrich Heine Univ, Dept Neurol, Dusseldorf, Germany

[9] Ctr Esclerosi Multiple Catalunya Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain

[10] Charles Univ Prague, Dept Neurol, Hradec Kralove, Czech Republic

[11] Charles Univ Prague, Ctr Clin Neurosci, Hradec Kralove, Czech Republic

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[14] Mellen Ctr MS Treatment & Res, Cleveland, OH USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P080

引用

页码：55 / 56

页数：2

共 50 条

[1] Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials
Steinman, Lawrence
Comi, Giancarlo
Cree, Bruce A. C.
Bar-Or, Amit
Selmaj, Krzysztof W.
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Huang, Vivian
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
[J]. NEUROLOGY, 2019, 92 (15)
[2] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study
Selmaj, K. W.
Cohen, J. A.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H.
Montalban, X.
Kappos, L.
Sheffield, J. K.
Krakovich, A.
Cheng, C.
Riolo, J.
Silva, D.
Cree, B. A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57
[3] Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-or, A.
Arnold, D. L.
Hartung, H-P
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Hetzer, J.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 473 - 474
[4] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D.
Hartung, H. P.
Montalban, X.
Havrdova, E.
Sheffield, J.
Chen, T.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J.
Cree, B.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 223
[5] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
Selmaj, K. W.
Ziemssen, T.
Comi, G.
Hartung, H. P.
Singal, M.
Thorpe, A.
Riolo, J. V.
Cheng, C. Y.
Sheffield, J. K.
Krakovich, A.
Vermersch, P.
Cree, B. A. C.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
[6] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
Selmaj, K. W.
Ziemssen, T.
Comi, G.
Hartung, H. -P.
Singal, M.
Riolo, J. V.
Cheng, C. -Y.
Sheffield, J. K.
Minton, N.
Vermersch, P.
Cree, B. A. C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
[7] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Krakovich, A.
Sheffield, J. K.
Cheng, C. -Y.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
[8] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
Steinman, L.
Comi, G.
Bar-Or, A.
Selmaj, K. W.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Janjua, A.
Huang, V.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
[9] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Hoogerheyde, J.
Afsari, S.
Sheffield, J. K.
Shi, F.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
[10] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Cree, Bruce A. C.
Selmaj, Krzysztof W.
Steinman, Lawrence
Comi, Giancarlo
Bar-Or, Amit
Arnold, Douglas L.
Hartung, Hans-Peter
Montalban, Xavier
Havrdova, Eva K.
Sheffield, James K.
Minton, Neil
Cheng, Chun-Yen
Silva, Diego
Kappos, Ludwig
Cohen, Jeffrey A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962

← 1 2 3 4 5 →